Log In
Print
BCIQ
Print
Print this Print this
 

QLT091001

  Manage Alerts
Collapse Summary General Information
Company QLT Inc.
DescriptionSynthetic form of 11-cis-retinal
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat impaired dark adaptation; Treat Leber's congenital amaurosis (LCA); Treat Leber's congenital amaurosis (LCA) and retinitis pigmentosa (RP); Treat retinitis pigmentosa (RP)
Regulatory Designation

U.S. - Fast Track (Treat Leber's congenital amaurosis (LCA));
U.S. - Orphan Drug (Treat retinitis pigmentosa (RP));
U.S. - Orphan Drug (Treat Leber's congenital amaurosis (LCA));
EU - Orphan Drug (Treat Leber's congenital amaurosis (LCA));
EU - Orphan Drug (Treat retinitis pigmentosa (RP))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today